J&J's Q3 2020 earnings call highlights strong performance across segments, particularly Pharmaceuticals, despite COVID-19 headwinds.  Management expressed optimism about continued procedure recovery in Medical Devices and positive volume trends in Pharmaceuticals.  The company's guidance for 2020 was revised upward, suggesting a more resilient outlook than previously anticipated.
[1]
